-
Alan Greenspan: longtime Fed chief with a divided legacy
-
Leinster boss Cullen to step down at end of next season
-
'Has-been' Belgium stars scorched after Iran World Cup draw
-
Oil falls on US-Iran progress; pound holds up as Starmer resigns
-
Starmer resigns as UK PM, Burnham favourite to take over
-
France, Germany reach deal on arms maker KNDS, paving way for IPO
-
Latest developments on Europe's heatwave
-
France set for hottest day yet of heatwave
-
Keir Starmer: downfall of UK's unpopular PM
-
Gaza's surfers seek solace in the sea
-
MEXC Lists Arcium (ARX) with 70,000 USDT in Airdrop+ Rewards
-
EasyJet rejects £5 bn takeover offer from US equity firm
-
Europe scorched by latest heatwave
-
UK's Starmer resigns as prime minister
-
Coffee break: Starbucks Korea stores pause for training after 'Tank Day' fiasco
-
Rightist leaders congratulate Colombian president-elect
-
Rare Philippine school shooting kills three teens, wounds seven
-
Kenya labour minister accused over Russian forced recruitment
-
Crude prices drop after 'positive' US-Iran talks
-
Some France schools closed for day of searing heat
-
Tuchel's England face defensive questions despite flying start at World Cup
-
Frankfurt to All Blacks: New Zealand pick first German-born player
-
Not just a hideout: Sahel forests provide base for jihadists
-
Ageless Messi has World Cup scoring record in his sights
-
Africa faces child surgery crisis as key anaesthesia runs out
-
Trump-backed populist wins razor-tight Colombia vote, sparking protests
-
J-Bay: S.Africa's surf mecca missing out on the global tour
-
'Progress', say mediators, after Iran-US talks towards ending war
-
Key points from the first round of Iran-US talks
-
European countries close schools, cancel trains as heatwave set to intensify
-
Crude prices drop, most stocks rise on 'positive' US-Iran talks
-
Slimy beans: Japanese natto disgusts and delights the world
-
Clark wins despite hecklers but hopes not to be 'heel of the PGA'
-
Cape Verde targeting World Cup knockout rounds after Uruguay draw: coach
-
Father's Day near-miss at US Open brings Burns to tears
-
New coach Rennie names Savea as All Blacks captain
-
Scheffler praises Clark's resolve in gutsy US Open triumph
-
Yamal kickstarts Spain World Cup bid as Cape Verde stun Uruguay
-
Cape Verde fight back for second World Cup draw against Uruguay
-
AI Financial Corporation Repurchases 1.43 Million Shares, Reinforcing Management's Conviction in Long-Term Value
-
VSee Health Highlights Business Operations and Financial Success After Recent Strategic Sale
-
OIC, IA, CNC, Penalty Abatement - Clear Start Tax Explains Which IRS Program Fits Which Taxpayer
-
Adcore Enters Strategic Partnership with TikTok as a Channel Sales Partner
-
TFS Financial Launches "Equipment Financing Powered by TFS" Program for WEX Customers
-
Worksport (NASDAQ:WKSP) Achieves 35% May Gross Margin, Lands Meyer Distribution, Targets $36M+ Revenue Run-Rate
-
Loop Industries Appoints Institutional Shareholder Jeff Geygan to Board; GVIC Outlines Intent to Increase Ownership Stake to 10%
-
Dateline Expands Music Valley HREE Project
-
GameSquare Stockholders Approve All Proposals at 2026 Annual Stockholder Meeting
-
Sky Quarry Enters Production Phase at Nevada's Only Refinery
-
SMX: The Age of Parity Is Permanent - And Certified Recycled Plastic Has Emerged as Its Economic Outcome
CTT Pharma Signs LOI for Clinical Trials and Testing of Nicotine Products
TAMPA, FL / ACCESS Newswire / June 22, 2026 / CTT Pharmaceutical Holdings, Inc. (OTCQB:CTTH) has signed an LOI with a testing company in the United States to conduct clinical trials and testing for several potential nicotine products for CTT Pharma. A partnership with this company would allow CTT the ability to independently go to market in the United States utilizing our patented technology. CTT Pharma will notify shareholders as more information becomes available.
About CTT Pharmaceutical Holdings, Inc.
CTT Pharmaceutical Holdings, Inc. is a pharmaceutical technology company specializing in the development and commercialization of thin film oral drug delivery systems designed to provide rapid onset, enhanced patient convenience, and efficient absorption. The Company's patented micelle based thin film platform is intended to offer a novel alternative to traditional dosage forms across pharmaceutical, therapeutic, and nutraceutical markets. CTT is focused on integrating scientific validation, scalable manufacturing, and regulatory preparedness to support long-term growth and product innovation.
Forward-Looking Statements
Forward-looking statements include statements regarding the Company's plans, objectives, expectations, and intentions, including potential future business operations. Words such as anticipate, believe, continue, could, estimate, expect, intend, may, plan, potential, predict, should, will, would and similar expressions identify forward-looking statements. These statements are based on management's current expectations and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied in forward-looking statements. Important factors that could cause such differences include, but are not limited to: the timing and outcome of a potential partnership. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to publicly update or revise any forward-looking statements.
CTT Pharmaceutical Holdings, Inc.
813-606-0060
SOURCE: CTT Pharmaceutical Holdings, Inc.
View the original press release on ACCESS Newswire
P.Mathewson--AMWN